Carolina Research

Greenville, North Carolina 27834-3761

0 studies enrolling now · 15 studies all time

What they study most

Crohn Disease, Eosinophilic Esophagitis, Erosive Esophagitis, Heartburn, Helicobacter Pylori Infection, Irritable Bowel Syndrome, Non-Erosive Gastro-Esophageal Reflux Disease, Nonalcoholic Steatohepatitis, Opioid-Induced Bowel Dysfunction, Ulcerative Colitis, Ulcerative Colitis and Crohn's Disease

Studies at this site

• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• Expanded Access Protocol for Patients With Eosinophilic Esophagitis — NO_LONGER_AVAILABLE
• 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) — Completed
• Entyvio (Vedolizumab) Long Term Safety Study — Completed
• The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis — Stopped early
• Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) — Completed
• A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease — Completed
• Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD) — Status unconfirmed
• Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis — Completed
• Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection — Completed
• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone — Completed
• Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone — Completed
• Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome — Completed